Encyclopedia of Clinical Neuropsychology

2018 Edition
| Editors: Jeffrey S. Kreutzer, John DeLuca, Bruce Caplan

Cholinergic System

  • Colleen E. JacksonEmail author
Reference work entry
DOI: https://doi.org/10.1007/978-3-319-57111-9_1113


Acetylcholinergic system


The cholinergic system is composed of organized nerve cells that use the neurotransmitter acetylcholine in the transduction of action potentials. These nerve cells are activated by or contain and release acetylcholine during the propagation of a nerve impulse. The cholinergic system has been associated with a number of cognitive functions, including memory, selective attention, and emotional processing.

Current Knowledge

Acetylcholine Synthesis and Metabolism

The synthesis of acetylcholine, the neurotransmitter used by nerve cells in the cholinergic system, requires choline, a natural amine found in the lipid bilayer of the cell membrane, and acetyl coenzyme A (acetyl-CoA), a thioester used in metabolic reactions and an acceptor and donor of acetyl groups. These molecules are catalyzed by choline acetyltransferase, an enzyme found only in acetylcholinergic cells, in order to produce acetylcholine.

In the metabolism of acetylcholine,...

This is a preview of subscription content, log in to check access.

References and Readings

  1. Bentley, P., Vuilleumier, P., Thiel, C., Driver, J., & Dolan, R. (2003). Cholinergic enhancement modulates neural correlates of selective attention and emotional processing. Neuroimage, 20, 58–70.PubMedCrossRefPubMedCentralGoogle Scholar
  2. Bodick, N. C., Offen, W. W., Levey, A. I., Cutler, N. R., Gauthier, S. G., Satlin, A., et al. (1997). Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Archives of Neurology, 54, 465–473.PubMedCrossRefPubMedCentralGoogle Scholar
  3. Gibbons, A., & Dean, B. (2016). The cholinergic system: An emerging drug target for schizophrenia. Current Pharmaceutical Design, 22, 2124–2133.PubMedCrossRefPubMedCentralGoogle Scholar
  4. Lameh, J., Burstein, E. S., Taylor, E., Weiner, D. M., Vanover, K. E., & Bonhaus, D. W. (2007). Pharmacology of N-desmethylclozapine. Pharmacology & Therapeutics, 115, 223–231.CrossRefGoogle Scholar
  5. Rangel-Gomez, M., & Meeter, M. (2016). Neurotransmitters and novelty: A systematic review. Journal of Psychopharmacology, 30, 3–12.PubMedCrossRefPubMedCentralGoogle Scholar
  6. Sarter, M., Givens, B., & Bruno, J. P. (2001). The cognitive neuroscience of sustained attention: Where top-down meets bottom-up. Brain Research Reviews, 35, 146–160.PubMedPubMedCentralCrossRefGoogle Scholar
  7. Sarter, M., Gehring, W. J., & Kozak, R. (2006). More attention must be paid: The neurobiology of attentional effort. Brain Research Reviews, 51, 145–160.PubMedPubMedCentralCrossRefGoogle Scholar
  8. Terry, A., & Buccafusco, J. (2003). The cholinergic hypothesis of age and Alzheimer’s disease-related cognitive deficits: Recent challenges and their implications for novel drug development. Journal of Pharmacology and Experimental Therapeutics, 306, 821–827.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG (outside the USA) 2018

Authors and Affiliations

  1. 1.VA Boston Healthcare SystemBostonUSA